These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37305994)

  • 1. Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways.
    Liang LW; Hasegawa K; Maurer MS; Reilly MP; Fifer MA; Shimada YJ
    Circ Heart Fail; 2023 Jun; 16(6):e010010. PubMed ID: 37305994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.
    Shimada YJ; Raita Y; Liang LW; Maurer MS; Hasegawa K; Fifer MA; Reilly MP
    Circ Heart Fail; 2021 Jul; 14(7):e007849. PubMed ID: 34192899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling Pathways Associated With Prior Cardiovascular Events in Hypertrophic Cardiomyopathy.
    Lee C; Liang LW; Hasegawa K; Maurer MS; Tower-Rader A; Fifer MA; Reilly M; Shimada YJ
    J Card Fail; 2024 Mar; 30(3):462-472. PubMed ID: 37562580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    Kuster DW; Mulders J; Ten Cate FJ; Michels M; Dos Remedios CG; da Costa Martins PA; van der Velden J; Oudejans CB
    J Mol Cell Cardiol; 2013 Dec; 65():59-66. PubMed ID: 24083979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics.
    Lumish HS; Liang LW; Hasegawa K; Maurer MS; Fifer MA; Reilly MP; Shimada YJ
    Heart; 2023 Nov; 109(24):1837-1843. PubMed ID: 37451849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Major Adverse Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy Using Proteomics Profiling.
    Shimada YJ; Raita Y; Liang LW; Maurer MS; Hasegawa K; Fifer MA; Reilly MP
    Circ Genom Precis Med; 2022 Dec; 15(6):e003546. PubMed ID: 36252118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the circulating transcriptome expression profile and identification of novel miRNA biomarkers in hypertrophic cardiomyopathy.
    Guo L; Cai Y; Wang B; Zhang F; Zhao H; Liu L; Tao L
    Eur J Med Res; 2023 Jun; 28(1):205. PubMed ID: 37391825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.
    Lumish HS; Sherrid MV; Janssen PML; Ferrari G; Hasegawa K; Castillero E; Adlestein E; Swistel DG; Topkara VK; Maurer MS; Reilly MP; Shimada YJ
    J Am Coll Cardiol; 2024 Nov; 84(20):1999-2011. PubMed ID: 39365226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
    Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
    J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy.
    Sucharov CC; Neltner B; Pietra AE; Karimpour-Fard A; Patel J; Ho CY; Miyamoto SD
    Circ Heart Fail; 2023 Jun; 16(6):e010291. PubMed ID: 36880380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.
    Angelopoulos A; Oikonomou E; Vogiatzi G; Antonopoulos A; Tsalamandris S; Georgakopoulos C; Papanikolaou P; Lazaros G; Charalambous G; Siasos G; Vlachopoulos C; Tousoulis D
    Curr Med Chem; 2021; 28(36):7400-7412. PubMed ID: 33820510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy.
    Ntelios D; Georgiou E; Alexouda S; Malousi A; Efthimiadis G; Tzimagiorgis G
    Heart Fail Rev; 2022 Jan; 27(1):281-294. PubMed ID: 33656618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of SMAD Signaling Pathway by miRNAs Associated with Myocardial Fibrosis: In silico Analysis of Target Gene Networks.
    Pisklova M; Osmak G; Favorova O
    Biochemistry (Mosc); 2022 Aug; 87(8):832-838. PubMed ID: 36171647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy.
    Garmany R; Bos JM; Tester DJ; Giudicessi JR; Dos Remedios CG; Dasari S; Nagaraj NK; Nair AA; Johnson KL; Ryan ZC; Maleszewski JJ; Ommen SR; Dearani JA; Ackerman MJ
    Circ Genom Precis Med; 2023 Apr; 16(2):e003756. PubMed ID: 36802768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating miR-499a-5p Is a Potential Biomarker of
    Baulina N; Pisklova M; Kiselev I; Chumakova O; Zateyshchikov D; Favorova O
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of pyroptosis-related genes as potential biomarkers for hypertrophic cardiomyopathy: A comprehensive bioinformatics analysis.
    Tang X; Shen Y; Lu Y; He W; Nie Y; Fang X; Cai J; Si X; Zhu Y
    Medicine (Baltimore); 2024 Jan; 103(4):e36799. PubMed ID: 38277535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic identification and analysis of dysregulated miRNA and transcription factor feed-forward loops in hypertrophic cardiomyopathy.
    Shi H; Li J; Song Q; Cheng L; Sun H; Fan W; Li J; Wang Z; Zhang G
    J Cell Mol Med; 2019 Jan; 23(1):306-316. PubMed ID: 30338905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy.
    Thottakara T; Lund N; Krämer E; Kirchhof P; Carrier L; Patten M
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling MiRNA-124 as a biomarker in hypertrophic cardiomyopathy: An innovative approach using machine learning and intelligent data analysis.
    Pisklova M; Osmak G
    Int J Cardiol; 2024 Sep; 410():132220. PubMed ID: 38815672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Levels of MicroRNAs in Hypertrophic Cardiomyopathy: The Relationship With Left Ventricular Hypertrophy, Left Atrial Dilatation and Ventricular Depolarisation-Repolarisation Parameters.
    Sonsöz MR; Yilmaz M; Cevik E; Orta H; Bilge AK; Elitok A; Onur I; Komurcu-Bayrak E
    Heart Lung Circ; 2022 Feb; 31(2):199-206. PubMed ID: 34088630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.